Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 23085775)

1.

Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance.

Babrzadeh F, Varghese V, Pacold M, Liu TF, Nyrén P, Schiffer C, Fessel WJ, Shafer RW.

J Antimicrob Chemother. 2013 Feb;68(2):414-8. doi: 10.1093/jac/dks409. Epub 2012 Oct 19.

2.

A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.

Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, Rovenska M, de Jong D, Chappey C, Goedegebuure IW, Heilek-Snyder G, Dulude D, Cammack N, Brakier-Gingras L, Konvalinka J, Parkin N, Kräusslich HG, Brun-Vezinet F, Boucher CA.

PLoS Med. 2007 Jan;4(1):e36.

3.

Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen.

Fisher R, van Zyl GU, Travers SA, Kosakovsky Pond SL, Engelbrech S, Murrell B, Scheffler K, Smith D.

J Virol. 2012 Jun;86(11):6231-7. doi: 10.1128/JVI.06541-11. Epub 2012 Mar 28.

4.

Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.

Aoki M, Venzon DJ, Koh Y, Aoki-Ogata H, Miyakawa T, Yoshimura K, Maeda K, Mitsuya H.

J Virol. 2009 Apr;83(7):3059-68. doi: 10.1128/JVI.02539-08. Epub 2009 Jan 28.

5.

Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.

Hertogs K, Bloor S, Kemp SD, Van den Eynde C, Alcorn TM, Pauwels R, Van Houtte M, Staszewski S, Miller V, Larder BA.

AIDS. 2000 Jun 16;14(9):1203-10.

PMID:
10894285
6.

Protease inhibitor resistance update: where are we now?

Kim R, Baxter JD.

AIDS Patient Care STDS. 2008 Apr;22(4):267-77. doi: 10.1089/apc.2007.0099.

PMID:
18422460
7.

A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes.

Doherty KM, Nakka P, King BM, Rhee SY, Holmes SP, Shafer RW, Radhakrishnan ML.

BMC Bioinformatics. 2011 Dec 15;12:477. doi: 10.1186/1471-2105-12-477.

8.

Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen.

Gianotti N, Seminari E, Lazzarin A, Boeri E, Clementi M, Danise A, Salpietro S, Fusetti G, Castagna A.

AIDS Res Hum Retroviruses. 2005 Jun;21(6):545-54.

PMID:
15989459
9.

Resistance to protease inhibitors.

Kuritzkes DR.

J HIV Ther. 2002 Nov;7(4):87-91. Review.

PMID:
12733606
10.

Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.

Gonzalez LM, Santos AF, Abecasis AB, Van Laethem K, Soares EA, Deforche K, Tanuri A, Camacho R, Vandamme AM, Soares MA.

J Antimicrob Chemother. 2008 Jun;61(6):1201-4. doi: 10.1093/jac/dkn099. Epub 2008 Mar 20.

11.

PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.

Dandache S, Coburn CA, Oliveira M, Allison TJ, Holloway MK, Wu JJ, Stranix BR, Panchal C, Wainberg MA, Vacca JP.

J Med Virol. 2008 Dec;80(12):2053-63. doi: 10.1002/jmv.21329.

PMID:
19040279
12.

TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.

Dierynck I, Van Marck H, Van Ginderen M, Jonckers TH, Nalam MN, Schiffer CA, Raoof A, Kraus G, Picchio G.

Antimicrob Agents Chemother. 2011 Dec;55(12):5723-31. doi: 10.1128/AAC.00748-11. Epub 2011 Sep 6.

13.

Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.

Lambert-Niclot S, Flandre P, Canestri A, Peytavin G, Blanc C, Agher R, Soulié C, Wirden M, Katlama C, Calvez V, Marcelin AG.

Antimicrob Agents Chemother. 2008 Feb;52(2):491-6. Epub 2007 Nov 26.

14.

Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.

Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, Rock D, Falloon J, Davey RT Jr, Dewar RL, Metcalf JA, Hammer S, Mellors JW, Coffin JM.

J Clin Microbiol. 2005 Jan;43(1):406-13.

15.

Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment.

Kagan RM, Cheung PK, Huard TK, Lewinski MA.

Antiviral Res. 2006 Aug;71(1):42-52. Epub 2006 Mar 23.

PMID:
16600392
16.
17.

Emergence of protease inhibitor resistance-associated mutations in plasma HIV-1 precedes that in proviruses of peripheral blood mononuclear cells by more than a year.

Bi X, Gatanaga H, Ida S, Tsuchiya K, Matsuoka-Aizawa S, Kimura S, Oka S.

J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):1-6.

PMID:
14501787
18.

Tissue culture drug resistance analysis of a novel HIV-1 protease inhibitor termed PL-100 in non-B HIV-1 subtypes.

Asahchop EL, Oliveira M, Brenner BG, Martinez-Cajas JL, Toni Td, Ntemgwa M, Moisi D, Dandache S, Stranix B, Tremblay CL, Wainberg MA.

Antiviral Res. 2010 Sep;87(3):367-72. doi: 10.1016/j.antiviral.2010.06.001. Epub 2010 Jun 10.

PMID:
20541566
19.
20.

Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis.

Mata-Munguía C, Escoto-Delgadillo M, Torres-Mendoza B, Flores-Soto M, Vázquez-Torres M, Gálvez-Gastelum F, Viniegra-Osorio A, Castillero-Manzano M, Vázquez-Valls E.

BMC Bioinformatics. 2014 Mar 15;15:72. doi: 10.1186/1471-2105-15-72.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk